Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) announced on Tuesday that its partner Eisai Co Ltd's (TYO:4523) Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosing has been accepted by the US Food and Drug Administration (FDA).
Leqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease. It is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option. The Prescription Drug User Fee Act (PDUFA) action date has been set to 31 August 2025.
The BLA is based on data from the Clarity AD (Study 301) open-label extension and modelling of observed data. The SC-AI 360 mg weekly maintenance regimen will allow patients who have completed the biweekly intravenous (IV) initiation phase, exact period under discussion with the FDA, to receive weekly doses that are expected to maintain the clinical and biomarker benefits.
Leqembi is already approved in the United States, Japan, China, Great Britain and other markets. In November 2024 the treatment received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval.
Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis
Merck launches Phase 3 trial for dengue vaccine candidate V181
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Mezzion Pharma obtains USD20m funding for udenafil Phase 3 clinical development for Fontan patients
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
MaxCyte and Ori Biotech partner to advance autologous cell therapy manufacturing
OptiBiotix announces publication of positive SlimBiome study in European Journal of Nutrition
Crossject advances paediatric development of ZEPIZURE Junior for epilepsy crisis management
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies